NLRC4

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Retrieved on: 
Wednesday, February 14, 2024
Inflammasome, PD, NLRC4, ALS, ASC, Inflammation, Traumatic brain injury, Nature Reviews Neurology, Neurology, Extracellular space, Neuropathology, Stroke, TBI, NLRP1, Multiple sclerosis, Intellectual disability, Therapy, Super Meat Boy, DSM-IV codes, Epilepsy, AIM2, Brain, Pharmaceutical industry

The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.

Key Points: 
  • The review article summarizes data demonstrating that inflammation resulting from activation of more than one type of inflammasome contributes to development of neurological diseases and that ASC specks lead to their progression.
  • ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes to block initiation and perpetuation of damaging inflammation.
  • (Nasdaq: ZVSA or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data from a review article published in Nature Reviews Neurology.
  • The authors concluded, “Use of inflammasome-targeted therapeutic approaches could improve existing therapeutic strategies for multiple neurological conditions.” To review the publication, Click Here .

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual Inflammasome Inhibitor K8

Retrieved on: 
Thursday, January 18, 2024
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Eye, Swelling, Patient, Therapy, ALS, Multiple sclerosis, NLRC4, University, Steroid, Inflammasome, DSM-IV codes, NLRP3, Geographic atrophy, Risk, Safety, Diabetic retinopathy, Toxicity, Inflammation, Retina, DME, Brain, Trial of the century, CNS, Pharmaceutical industry

Inflammasome Therapeutics ( https://www.inflam.com ), a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema (DME).

Key Points: 
  • Inflammasome Therapeutics ( https://www.inflam.com ), a clinical-stage, private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a Phase 1 study of one of the company’s novel compounds in the treatment of diabetic macular edema (DME).
  • The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy.
  • This investigator-sponsored study, led by Dr. Michelle Abou-Jaoude of the University of Kentucky, is expected to be completed this year and will enroll five patients.
  • We initially are targeting a time period of three months,” said Dr. Paul Ashton, CEO of Inflammasome Therapeutics.

ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Microelectrode, ASC, University, Inflammasome, AIM2, Associate professor, DSM-IV codes, ME, Quality of life, NLRP3, Dystonia, Biomedical engineering, Essential tremor, Wallace H. Coulter Department of Biomedical Engineering, Parkinson's disease, Biomedicine, Patient, NLRP1, Brain, Invention, NLRC4, Therapy, Disease, Medical imaging, Pharmaceutical industry, Medical device, Biomaterial, Medicine

Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia

Key Points: 
  • Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia
    WESTON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.
  • In the paper titled, “Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants,” the researchers reported:
    Multiple types of inflammasome sensor molecules (NLRP1, NLRP3, AIM2, and NLRC4) were upregulated following ME implant injury
    NLRP1 and NLRP3, which were upregulated by 48 hours and remained distinctly elevated at 4 weeks, play a vital role in activation of inflammasome complexes during acute and sub-chronic periods following ME-induced injury
    In addition to sensor molecules, ASC and Caspase-1 were persistently elevated throughout the implant duration
    Sustained presence of gasdermin D provides evidence of elevated pyroptosis (“cell death”) occurring at the injury site, which coincided with a decrease in neuronal density
    “Deep brain stimulation is an important therapeutic option to help maintain quality of life in patients with movement disorders whose symptoms are not effectively controlled by medication,” stated Dr. Abhishek Prasad, Associate Professor, the Department of Biomedical Engineering at the University of Miami Miller School of Medicine.
  • “Our results not only demonstrate that continuous activation of inflammasomes contribute to neuroinflammation at the ME-tissue interface, but also reveal the therapeutic potential of targeting inflammasomes to attenuate the foreign body response to cortical implants.”
    “The research published in Biomaterials provides additional support for the therapeutic potential of ZyVersa’s proprietary monoclonal antibody inflammasome ASC inhibitor, IC 100, in neurological injury and disease,” indicated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Preclinical studies have demonstrated reduced inflammatory activity and/or improved outcomes in two different models of brain injury, spinal cord injury, age-related inflammation Alzheimer’s disease, and multiple sclerosis.”

New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer’s Disease and Multiple Sclerosis

Retrieved on: 
Monday, December 6, 2021
Health, Other Health, General Health, Research, Pharmaceutical, Science, CEO, Bill, Lupus, Multiple sclerosis, NLRC4, University, Inflammasome, Boehringer Ingelheim, Center, View, Research, Risk, NLRP3, Macular degeneration, III, Therapy, Bill & Melinda Gates Foundation, Toxicity, Degenerative disease, HIV, Medical device, Pharmaceutical industry

Advancing science now shows that things are a little more complicated, and opens up the opportunity to effectively target these diseases.

Key Points: 
  • Advancing science now shows that things are a little more complicated, and opens up the opportunity to effectively target these diseases.
  • This research published Friday, points to the role that the NLRC4 inflammasome plays in lupus and macular degeneration, specifically.
  • Kamuvudines have been found to be extremely effective in pre-clinical models of macular degeneration, Parkinsons disease and multiple sclerosis.
  • Unfortunately, NRTIs are relatively toxic and cant be used to treat people with diseases like macular degeneration, multiple sclerosis and lupus.

FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Retrieved on: 
Tuesday, July 14, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Autoinflammatory syndromes, Medical specialties, Branches of biology, Health, Periodic fever syndrome, Cryopyrin-associated periodic syndrome, NALP3, Caps, Orphan drug, NLRP, Interleukin 1 beta, NLRC4, Inflazome, the NLPR3 Inflammasome, Cryopyrin-associated periodic syndromes, Orphan Drug Designation

Inflazome ( inflazome.com ), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that it has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for Inzomelid in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS).

Key Points: 
  • Inflazome ( inflazome.com ), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that it has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for Inzomelid in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS).
  • Orphan Drug Designation is an important regulatory milestone granted to drugs that are intended to treat rare diseases and conditions, such as CAPS.
  • Inzomelid is under development as an orally available, brain-penetrant drug and Somalix is under development as an orally available, peripherally-restricted drug.
  • Cryopyrin-associated periodic syndromes (CAPS), also called cryopyrin-associated autoinflammatory syndromes, are three diseases related to a defect in the NLRP3 gene.

AB2 Bio Appoints Michael Soldan CEO

Retrieved on: 
Tuesday, March 3, 2020
Hemophagocytic lymphohistiocytosis, HLH, Medical specialties, Fresenius, École Polytechnique Fédérale de Lausanne, NLRC4, Histiocytosis, Soldan, Economy of Germany

Prior to Fresenius Kabi, Dr. Soldan was with Merck Group, where he spent two years heading the biosimilars business.

Key Points: 
  • Prior to Fresenius Kabi, Dr. Soldan was with Merck Group, where he spent two years heading the biosimilars business.
  • I am very pleased to welcome Michael Soldan to AB2 Bio, where he will bring the benefit of his impressive and wide-ranging career in the pharmaceuticals industry.
  • AB2 Bio is conducting a pivotal Phase 3 clinical trial of Tadekinigalfa in primary, interleukin-18 driven Hemophagocytic Lymphohistiocytosis (HLH) patientswith NLRC4 mutation or XIAP deficiency.
  • AB2 Bio Ltd ( http://www.ab2bio.com/ ) is a private advanced clinical-stage biotech company located in the Innovation Park at the Ecole polytechnique federale de Lausanne (EPFL), Switzerland.